nach oben

Journal of Urban Health

Erschienen in:

01.02.2015

Buprenorphine Maintenance Treatment Retention Improves Nationally Recommended Preventive Primary Care Screenings when Integrated into Urban Federally Qualified Health Centers

verfasst von: Marwan S. Haddad, Alexei Zelenev, Frederick L. Altice

Erschienen in: Journal of Urban Health | Ausgabe 1/2015

Einloggen, um Zugang zu erhalten

Abstract

Buprenorphine maintenance therapy (BMT) expands treatment access for opioid dependence and can be integrated into primary health-care settings. Treating opioid dependence, however, should ideally improve other aspects of overall health, including preventive services. Therefore, we examined how BMT affects preventive health-care outcomes, specifically nine nationally recommended primary care quality health-care indicators (QHIs), within federally qualified health centers (FQHCs) from an observational cohort study of 266 opioid-dependent patients initiating BMT between 07/01/07 and 11/30/08 within Connecticut’s largest FQHC network. Nine nationally recommended preventive QHIs were collected longitudinally from electronic health records, including screening for chronic infections, metabolic conditions, and cancer. A composite QHI score (QHI-S), based on the percentage of eligible QHIs achieved, was categorized as QHI-S ≥80 % (recommended) and ≥90 % (optimal). The proportion of subjects achieving a composite QHI-S ≥80 and ≥90 % was 57.1 and 28.6 %, respectively. Screening was highest for hypertension (91.0 %), hepatitis C (80.1 %), hepatitis B (76.3 %), human immunodeficiency virus (71.4 %), and hyperlipidemia (72.9 %) and lower for syphilis (49.3 %) and cervical (58.5 %), breast (44.4 %), and colorectal (48.7 %) cancer. Achieving QHI-S ≥80 % was positively and independently associated with ≥3-month BMT retention (adjusted odds ratio (AOR) = 2.19; 95 % confidence interval (CI) = 1.18–4.04) and BMT prescription by primary care providers (PCPs) rather than addiction psychiatric specialists (AOR = 3.38; 95 % CI = 1.78–6.37), and negatively with being female (AOR = 0.30; 95 % CI = 0.16–0.55). Within primary health-care settings, achieving greater nationally recommended health-care screenings or QHIs was associated with being able to successfully retain patients on buprenorphine longer (3 months or more) and when buprenorphine was prescribed simultaneously by PCPs rather than psychiatric specialists. Decreased preventive screening for opioid-dependent women, however, may require gender-based strategies for achieving health-care parity. When patients can be retained, integrating BMT into urban FQHCs is associated with improved health outcomes including increased multiple preventive health-care screenings.

Degenhardt L, Whiteford HA, Ferrari AJ, et al. Global burden of disease attributable to illicit drug use and dependence: findings from the Global Burden of Disease Study 2010. Lancet. 2013; 382(9904): 1564–1574.CrossRefPubMed

Substance Abuse and Mental Health Services Administration (SAMHSA). The TEDS Report: characteristics of adolescent heroin admissions. Rockville, MD: Office of Applied Studies; 2009.

Johnston LD, O’Malley PM, Bachman JG, Schulenberg JE. Monitoring the Future national results on adolescent drug use: overview of key findings, 2009. National Institutes on Drug Abuse, ed. Bethesda, MD; 2010: (NIH Publication No. 10–7583)

Substance Abuse and Mental Health Services Administration (SAMHSA). Results from the 2011 National Survey on Drug Use and Health: summary of national findings. Vol NSDUH Series H-44, HHS Publication No. (SMA) 12-4713. Rockville, MD; 2012.

Substance Abuse and Mental Health Services Administration (SAMHSA). The DAWN Report: Highlights of the 2010 Drug Abuse Warning Network (DAWN) findings on drug-related emergency department visits. Center for Behavioral Health Statistics and Quality, ed. Rockville, MD; 2012.

SAMHSA. Results from the 2010 National Survey on Drug Use and Health: national findings. Office of Applied Studies, ed. HHS Publication No. SMA 10-4856: Rockville, MD; 2011.

Lankenau SE, Teti M, Silva K, Jackson Bloom J, Harocopos A, Treese M. Initiation into prescription opioid misuse amongst young injection drug users. Int J Drug Pol. 2012; 23(1): 37–44.CrossRef

Altice FL, Kamarulzaman A, Soriano VV, Schechter M, Friedland GH. Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs. Lancet. 2010; 376(9738): 59–79.CrossRef

Kleber HD. Pharmacologic treatments for heroin and cocaine dependence. Am J Addict. 2003; 12(Suppl 2): S5–S18.CrossRefPubMed

10.

De Alba I, Samet JH, Saitz R. Burden of medical illness in drug- and alcohol-dependent persons without primary care. Am J Addict. 2004; 13(1): 33–45.CrossRefPubMed

11.

Swindle RW, Rao JK, Helmy A, et al. Integrating clinical nurse specialists into the treatment of primary care patients with depression. Int J Psychiatr Med. 2003; 33(1): 17–37.CrossRef

12.

Lieber CS. Hepatic and other medical disorders of alcoholism: from pathogenesis to treatment. J Stud Alcohol. 1998; 59(1): 9–25.PubMed

13.

Saitz R, Horton NJ, Larson MJ, Winter M, Samet JH. Primary medical care and reductions in addiction severity: a prospective cohort study. Addict. 2005; 100(1): 70–78.CrossRef

14.

Connock M, Juarez-Garcia A, Jowett S, et al. Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Health Technol Assess. 2007; 11(9): 1–171.CrossRefPubMed

15.

Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2008; 2: CD002207.PubMed

16.

Basu S, Smith-Rohrberg D, Bruce RD, Altice FL. Models for integrating buprenorphine therapy into the primary HIV care setting. Clin Infect Dis. 2006; 42(5): 716–721.CrossRefPubMed

17.

Altice FL, Sullivan LE, Smith-Rohrberg D, Basu S, Stancliff S, Eldred L. The potential role of buprenorphine in the treatment of opioid dependence in HIV-infected individuals and in HIV infection prevention. Clin Infect Dis. 2006; 43(Suppl 4): S178–183.CrossRefPubMed

18.

Peikes D, Zutshi A, Genevro J, Smith K, Parchman M, Meyers D. Early evidence on the patient-centered medical home. Final report In: Agency for Healthcare Research and Quality, ed. Rockville, MD: Prepared by Mathematica Policy Research; 2012: AHRQ Publication No. 12-0020-EF. Accessed on June 17, 2013 at http://pcmh.ahrq.gov/portal/server.pt/gateway/PTARGS_0020_11787_957210_957210_957210_957218/Early%957220Evidence%957220on%957220the%957220PCMH%957202%952028%952012.pdf.

19.

Butler M, Kane RL, McAlpine D, et al. Integration of mental health/Substance abuse and primary care. In: Agency for Healthcare Research and Quality, ed. Vol Evidence Report/Technology Assessment Number 173: Agency for Healthcare Research and Quality; 2008.

20.

Connecticut Department of Mental Health and Addiction Services. An evaluation of racial and ethnic health disparities in the state inpatient services. In: Office of Multicultural Affairs HDI, ed. Hartford, CT: Hartford Department of Public Health; 2008: Accessed on June 17, 2013 at: http://www.ct.gov/dmhas/lib/dmhas/oma/disparitiesreport.pdf.

21.

Agency for Healthcare Research and Quality (AHRQ). 2012 national healthcare disparities report. Rockville, MD; 2013: Accessed on July 9, 2013 at: http://www.ahrq.gov/research/findings/nhqrdr/nhdr2012/index.html.

22.

Alford DP, LaBelle CT, Kretsch N, et al. Collaborative care of opioid-addicted patients in primary care using buprenorphine: five-year experience. Arch Intern Med. 2011; 171(5): 425–431.CrossRefPubMedCentralPubMed

23.

Khan MR, Berger A, Hemberg J, O’Neill A, Dyer TP, Smyrk K. Non-injection and injection drug use and STI/HIV risk in the United States: the degree to which sexual risk behaviors versus sex with an STI-infected partner account for infection transmission among drug users. AIDS Behav. 2013; 17(3): 1185–1194.CrossRefPubMedCentralPubMed

24.

Vlahov D, Wang C, Ompad D, et al. Mortality risk among recent-onset injection drug users in five U.S. cities. Subst Use Misuse. 2008; 43(3–4): 413–428.CrossRefPubMed

25.

Degenhardt L, Hall W, Warner-Smith M. Using cohort studies to estimate mortality among injecting drug users that is not attributable to AIDS. Sex Transm Infect. 2006; 82(Suppl 3): S56–63.

26.

Bargagli AM, Sperati A, Davoli M, Forastiere F, Perucci CA. Mortality among problem drug users in Rome: an 18-year follow-up study, 1980–97. Addict. 2001; 96(10): 1455–1463.CrossRef

27.

Lloyd-Smith E, Brodkin E, Wood E, et al. Impact of HAART and injection drug use on life expectancy of two HIV-positive cohorts in British Columbia. AIDS. 2006; 20(3): 445–450.CrossRefPubMed

28.

Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet. 2008; 372(9635): 293–299.CrossRef

29.

van Sighem AI, Gras LA, Reiss P, Brinkman K, de Wolf F. Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals. AIDS. 2010; 24(10): 1527–1535.CrossRefPubMed

30.

Haddad MS, Zelenev A, Altice FL. Integrating buprenorphine maintenance therapy into federally qualified health centers: real-world substance abuse treatment outcomes. Drug Alcohol Depend. 2013; 131(1–2): 127–135.CrossRefPubMedCentralPubMed

31.

Altice FL, Bruce RD, Lucas GM, et al. HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study. J Acquir Immune Defic Syndr. 2011; 56(Suppl 1): S22–32.CrossRefPubMedCentralPubMed

32.

Fiellin DA, Moore BA, Sullivan LE, et al. Long-term treatment with buprenorphine/naloxone in primary care: results at 2–5 years. Am J Addict. 2008; 17(2): 116–120.CrossRefPubMed

33.

Soeffing JM, Martin LD, Fingerhood MI, Jasinski DR, Rastegar DA. Buprenorphine maintenance treatment in a primary care setting: outcomes at 1 year. J Subst Abuse Treat. 2009; 37(4): 426–430.CrossRefPubMed

34.

Stein MD, Cioe P, Friedmann PD. Buprenorphine retention in primary care. J Gen Intern Med. 2005; 20(11): 1038–1041.CrossRefPubMedCentralPubMed

35.

Schwarz R, Zelenev A, Bruce RD, Altice FL. Retention on buprenorphine treatment reduces emergency department utilization, but not hospitalization, among treatment-seeking patients with opioid dependence. J Subst Abus Treat. 2012; 43(4): 451–457.CrossRef

36.

Gelberg L, Andersen RM, Leake BD. The behavioral model for vulnerable populations: application to medical care use and outcomes for homeless people. Health Serv Res. 2000; 34(6): 1273–1302.PubMedCentralPubMed

37.

Stein JA, Andersen R, Gelberg L. Applying the Gelberg–Andersen behavioral model for vulnerable populations to health services utilization in homeless women. J Health Psychol. 2007; 12(5): 791–804.CrossRefPubMed

38.

Branson BM, Handsfield HH, Lampe MA, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep. 2006; 55(RR-14): 1–17.PubMed

39.

Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. In: Department of Health and Human Services, ed. Washington, DC; 2011:1–166; Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed February 12, 2011.

40.

Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatol. 2009; 49(4): 1335–1374.CrossRef

41.

Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatol. 2009; 50(3): 661–662.CrossRef

42.

Calonge N. Screening for syphilis infection: recommendation statement. Ann Fam Med. 2004; 2(4): 362–365.CrossRefPubMed

43.

U.S. Preventive Services Task Force. Screening for lipid disorders in adults: U.S. Preventive services task force recommendation statement. AHRQ Publication No. 08-05114-EF-2, ed. Washington, DC; 2008: Accessed at http://www.uspreventiveservicestaskforce.org/uspstf08/lipid/lipidrs.htm on December 13, 2012.

44.

American College of Gynecologists and Obstetricians. Cervical cytology screening. In: Clinical management guidelines for obstetrician-gynecologists, ed. Washington, DC: ACOG Practice Bulletin No. 109. 2009.

45.

American College of Gynecologists and Obstetricians. Breast cancer screening. Washington: ACOG Practice Bulletin No. 42; 2003.

46.

U.S. Preventive Services Task Force. Screening for colorectal cancer: clinical summary of U.S. Preventive Services Task Force recommendation In: AHRQ Publication No. 08-05124-EF-4, ed. Washington, DC; 2008: Accessed at http://www.uspreventiveservicestaskforce.org/uspstf08/colocancer/colosum.htm on April 11, 2012.

47.

Preventive Services US. Task Force. Screening for high blood pressure: U.S. Preventive services task force reaffirmation recommendation statement. Ann Intern Med. 2007; 147(11): 783–786.CrossRef

48.

Korthuis PT, Fiellin DA, Fu R, et al. Improving adherence to HIV quality of care indicators in persons with opioid dependence: the role of buprenorphine. J Acquir Immune Defic Syndr. 2011; 56(Suppl 1): S83–90.CrossRefPubMedCentralPubMed

49.

Jackman S. Estimation and inference via Bayesian simulation: an introduction to Markov chain Monte Carlo. Am J Polit Sci. 2000; 44(2): 375–404.CrossRef

50.

Sylla L, Bruce RD, Kamarulzaman A, Altice FL. Integration and co-location of HIV/AIDS, tuberculosis and drug treatment services. Int J Drug Pol. 2007; 18(4): 306–312.CrossRef

51.

World Health Organization. Policy guidelines for collaborative TB and HIV services for injecting and other drug users: an integrated approach. In: Stop TB Department, ed. Geneva; 2008.

52.

Centers for Disease Control and Prevention. Integrated prevention services for HIV infection, viral hepatitis, sexually transmitted diseases, and tuberculosis for persons who use drugs illicitly: summary guidance from CDC and the U.S. Department of Health and Human Services. MMWR Recomm Rep. 2012; 61(RR-5): 1–40.

53.

Abrams MT, Myers CS, Feldman SM, et al. Cervical cancer screening and acute care visits among medicaid enrollees with mental and substance use disorders. Psychiatr Serv. 2012; 63(8): 815–822.CrossRefPubMedCentralPubMed

54.

Pleis JR, Ward BW, Lucas JW. Summary health statistics for U.S. adults: National Health Interview Survey. Vital Health Stat 10. 2009; 2010(249): 1–207.

55.

Chadwick JJ, Andrade LF, Altice FL, Petry NM. Correlates of having never been HIV tested among entrants to substance abuse treatment clinics: empiric findings from real-world new england settings. J Psychoactive Drugs. 2014; 46(3): 208–214.CrossRefPubMed

56.

D’Aunno T, Pollack HA, Jiang L, Metsch LR, Friedmann PD. HIV testing in the nation’s opioid treatment programs, 2005–2011: the role of state regulations. Health Serv Res. 2014; 49(1): 230–248.CrossRefPubMedCentralPubMed

57.

Edelman EJ, Dinh AT, Moore BA, Schottenfeld RS, Fiellin DA, Sullivan LE. Human immunodeficiency virus testing practices among buprenorphine-prescribing physicians. J Addict Med. 2012; 6(2): 159–165.CrossRefPubMedCentralPubMed

58.

Brown LS Jr, Kritz SA, Goldsmith RJ, et al. Characteristics of substance abuse treatment programs providing services for HIV/AIDS, hepatitis C virus infection, and sexually transmitted infections: the National Drug Abuse Treatment Clinical Trials Network. J Subst Abuse Treat. 2006; 30(4): 315–321.CrossRefPubMedCentralPubMed

59.

Weinbaum CM, Williams I, Mast EE, et al. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep. 2008; 57(RR-8): 1–20.PubMed

60.

Springer SA, Qiu J, Saber-Tehrani AS, Altice FL. Retention on buprenorphine is associated with high levels of maximal viral suppression among HIV-infected opioid dependent released prisoners. PLoS One. 2012; 7(5): e38335.CrossRefPubMedCentralPubMed

61.

Rosenman MB, Tao G, Szucs KA, Wang J, Ambuehl R, Mahon BE. Prenatal syphilis screening rates measured using medicaid claims and electronic medical records. Sex Transm Dis. 2008; 35(4): 387–392.CrossRefPubMed

62.

White DA, Alter HJ, Irvin NA, Clark MC, Frazee BW. Low rate of syphilis screening among high-risk emergency department patients tested for gonorrhea and chlamydia infections. Sex Transm Dis. 2012; 39(4): 286–290.CrossRefPubMed

63.

Centers for Disease Control and Prevention (CDC). State incidence of syphilis reporting, 2008. Atlanta, GA; 2009: Accessed on July 12, 2013 at: http://www.cdc.gov/std/syphilis2008/AllSyphilisProfiles-2008.pdf.

64.

Callander D, Baker D, Chen M, Guy R. Including syphilis testing as part of standard HIV management checks and improved syphilis screening in primary care. Sex Transm Dis. 2013; 40(4): 338–340.CrossRefPubMed

65.

Adams PF, Heyman KM, Vickerie JL. Summary health statistics for the U.S. population: National Health Interview Survey. Vital Health Stat 10. 2008; 2009(243): 1–104.

66.

Centers for Disease Control and Prevention (CDC). Behavioral risk factor surveillance system annual survey data: 2009 survey data. In: Office of Surveillance E, and Laboratory Services, ed. Atlanta, GA; 2009: Accessed on April 12, 2012 at http://www.cdc.gov/brfss/technical_infodata/surveydata/2009.htm.

67.

Ford ES, Li C, Pearson WS, Zhao G, Mokdad AH. Trends in hypercholesterolemia, treatment and control among United States adults. Int J Cardiol. 2010; 140(2): 226–235.CrossRefPubMed

68.

Gillespie CD, Keenan NL, Miner JB, Hong Y. Screening for lipid disorders among adults—National Health and Nutrition Examination Survey, United States, 2005–2008. MMWR Morb Mortal Wkly Rep. 2012; 61(Suppl): 26–31.PubMed

69.

Ostchega Y, Yoon SS, Hughes J, Louis T. Hypertension awareness, treatment, and control—continued disparities in adults: United States, 2005–2006. NCHS Data Brief. 2008(3):1–8.

70.

Meyer JP, Springer SA, Altice FL. Substance abuse, violence, and HIV in women: a literature review of the syndemic. J Womens Health. 2011; 20(7): 991–1006.CrossRef

71.

Coffield AB, Maciosek MV, McGinnis JM, et al. Priorities among recommended clinical preventive services. Am J Prev Med. 2001; 21(1): 1–9.CrossRefPubMed

72.

Nutting PA, Baier M, Werner JJ, Cutter G, Conry C, Stewart L. Competing demands in the office visit: what influences mammography recommendations? J Am Board Fam Pract. 2001; 14(5): 352–361.PubMed

73.

Joseph DA, King JB, Miller JW, Richardson LC. Prevalence of colorectal cancer screening among adults—Behavioral Risk Factor Surveillance System, United States, 2010. MMWR Morb Mortal Wkly Rep. 2012; 61(Suppl): 51–56.PubMed

74.

Miller JW, King JB, Joseph DA, Richardson LC. Breast cancer screening among adult women—Behavioral Risk Factor Surveillance System, United States, 2010. MMWR Morb Mortal Wkly Rep. 2012; 61(Suppl): 46–50.PubMed

75.

Korthuis PT, Tozzi MJ, Nandi V, et al. Improved quality of life for opioid-dependent patients receiving buprenorphine treatment in HIV clinics. J Acquir Immune Defic Syndr. 2011; 56(Suppl 1): S39–45.CrossRefPubMedCentralPubMed

76.

Bachireddy C, Soule MC, Izenberg JM, Dvoryak S, Dumchev K, Altice FL. Integration of health services improves multiple healthcare outcomes among HIV-infected people who inject drugs in Ukraine. Drug Alcohol Depend. 2014; 134: 106–114.CrossRefPubMed

77.

Edelman EJ, Chantarat T, Caffrey S, et al. The impact of buprenorphine/naloxone treatment on HIV risk behaviors among HIV-infected, opioid-dependent patients. Drug Alcohol Depend. 2014; 139: 79–85.CrossRefPubMed

78.

Schwarz RK, Bruce RD, Ball SA, Herme M, Altice FL. Comparison of tuberculin skin testing reactivity in opioid-dependent patients seeking treatment with methadone versus buprenorphine: policy implications for tuberculosis screening. Am J Drug Alcohol Abuse. 2009; 35(6): 439–444.CrossRefPubMed

79.

Weiss L, Netherland J, Egan JE, et al. Integration of buprenorphine/naloxone treatment into HIV clinical care: lessons from the BHIVES collaborative. J Acquir Immune Defic Syndr. 2011; 56(Suppl 1): S68–75.CrossRefPubMed

80.

Centers for Disease Control and Prevention. Breast cancer screening and socioeconomic status—35 metropolitan areas, 2000 and 2002. MMWR Morb Mortal Wkly Rep. 2005; 54(39): 981–985.

81.

Coughlin SS, King J, Richards TB, Ekwueme DU. Cervical cancer screening among women in metropolitan areas of the United States by individual-level and area-based measures of socioeconomic status, 2000 to 2002. Cancer Epidemiol Biomarkers Prev. 2006; 15(11): 2154–2159.CrossRefPubMed

82.

Meyer JP, Zelenev A, Wickersham JA, Williams CT, Teixeira PA, Altice FL. Women released from jail experience suboptimal HIV treatment outcomes compared to men: results from a multi-center study. Am J Public Health. 2014; 104(3): 434–41.CrossRefPubMedCentralPubMed

83.

Aziz M, Smith KY. Challenges and successes in linking HIV-infected women to care in the United States. Clin Infect Dis. 2011; 52(Suppl 2): S231–237.CrossRefPubMed

84.

Meyer JP, Zelenev A, Wickersham JA, Williams CT, Teixeira PA, Altice FL. Gender disparities in HIV treatment outcomes following release from jail: results from a multicenter study. Am J Public Health. 2014; 104(3): 434–441.CrossRefPubMedCentralPubMed

85.

Hall JA, Irish JT, Roter DL, Ehrlich CM, Miller LH. Satisfaction, gender, and communication in medical visits. Med Care. 1994; 32(12): 1216–1231.CrossRefPubMed

86.

Hall JA, Irish JT, Roter DL, Ehrlich CM, Miller LH. Gender in medical encounters: an analysis of physician and patient communication in a primary care setting. Health Psychol. 1994; 13(5): 384–392.CrossRefPubMed

87.

Substance Abuse and Mental Health Services Administration (SAMHSA). Results from the 2008 National Survey on Drug Use and Health: national findings. Rockville: Office of Applied Studies, NSDUH Series H-36, HHS Publication No. SMA 09–4434; 2009.

88.

Substance Abuse and Mental Health Services Administration (SAMHSA). Results from the 2011 national survey on drug use and health: summary of national findings. Rockville, MD: NSDUH Series H-44, HHS Publication No. (SMA) 12–4713; 2012.

89.

Walley AY, Alperen JK, Cheng DM, et al. Office-based management of opioid dependence with buprenorphine: clinical practices and barriers. J Gen Intern Med. 2008; 23(9): 1393–1398.CrossRefPubMedCentralPubMed

Titel: Buprenorphine Maintenance Treatment Retention Improves Nationally Recommended Preventive Primary Care Screenings when Integrated into Urban Federally Qualified Health Centers
verfasst von: Marwan S. Haddad
Alexei Zelenev
Frederick L. Altice
Publikationsdatum: 01.02.2015
Verlag: Springer US
Erschienen in: Journal of Urban Health / Ausgabe 1/2015
Print ISSN: 1099-3460
Elektronische ISSN: 1468-2869
DOI: https://doi.org/10.1007/s11524-014-9924-1

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2015

Disentangling Race and Social Context in Understanding Disparities in Chronic Conditions among Men

Breast Cancer Treatment among African American Women in North St. Louis, Missouri

Correlates of HIV Testing among African American and Latino Church Congregants: The Role of HIV Stigmatizing Attitudes and Discussions about HIV

Objective Measures of the Built Environment and Physical Activity in Children: From Walkability to Moveability

Estimating the Number of Men Who Have Sex with Men by Race/Ethnicity at the County Level in Texas

Connecting the Dots: Examining Transgender Women’s Utilization of Transition-Related Medical Care and Associations with Mental Health, Substance Use, and HIV